Juno, Novartis settle cancer patent spat for $12 million
- In a dispute involving a hospital, a university, and two major pharma companies, Novartis will end up paying Juno Therapeutics a total of $12.25 million plus milestones for use of its chimeric receptor technology.
- In this dispute, St. Jude's Hospital and Juno Therapeutics are aligned versus the University of Pennsylvania and Novartis.
- The patent suit has been settled and all claims have been dismissed.
On one side, there's St. Jude's Research Hospital and Juno Therapeutics. On the other side, there's Novartis and the University of Pennsylvania. Each is partnered with the other with the goal of advancing cancer research, with a focus on chimeric receptors—the basis for the latest mega-trend in oncology R&D, immunotherapy.
Under the agreement between the four parties, Juno will receive $12.25 million, which it will share with St. Jude's.